LO-BLISOVI FE
Clinical safety rating
cautionComprehensive clinical and safety monograph for LO-BLISOVI FE (LO-BLISOVI FE).
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; norethindrone induces endometrial changes, increasing cervical mucus viscosity.
| Metabolism | Hepatic via CYP3A4 (ethinyl estradiol) and primarily conjugation (norethindrone); first-pass metabolism. |
| Excretion | Renal (approximately 60% as metabolites, 10-15% as unchanged drug); fecal (about 20-30%) |
| Half-life | Terminal elimination half-life: 15-18 hours for ethinyl estradiol; clinical context: supports once-daily dosing |
| Protein binding | Ethinyl estradiol: 95-98% bound to albumin and sex hormone-binding globulin (SHBG) |
| Volume of Distribution | Ethinyl estradiol: 2-5 L/kg; indicates extensive tissue distribution |
| Bioavailability | Oral: ethinyl estradiol approximately 40-50% (first-pass metabolism) |
| Onset of Action | Oral: contraceptive effect established within 7 days of continuous dosing |
| Duration of Action | Duration: 24 hours; requires daily dosing for maintained suppression of ovulation |
| Molecular Weight | 376.88 |
| Action Class | Combination Oral Contraceptive (Estrogen-Progestin) |
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required in renal impairment. Use with caution if severe renal impairment or nephrotic syndrome due to potential fluid retention. |
| Liver impairment | Contraindicated in acute hepatic disease or severe cirrhosis (Child-Pugh class C). Not recommended in moderate impairment (Child-Pugh B) without specialist advice. No data for mild (Child-Pugh A); use caution. |
| Pediatric use | Not indicated in pediatric patients before menarche. For postmenarchal females, same adult dose may be used; weight-based dosing not established. |
| Geriatric use | Not indicated in postmenopausal women. No specific geriatric dose adjustments; consider increased risk of thrombotic events and comorbidities. |
| 1st trimester | Contraindicated due to risk of congenital defects; use only if no alternative. |
| 2nd trimester | Avoid due to potential for thromboembolic events and possible fetal harm. |
| 3rd trimester | Avoid; may induce premature closure of ductus arteriosus and impair fetal renal function. |
Clinical note
Comprehensive clinical and safety monograph for LO-BLISOVI FE (LO-BLISOVI FE).
| Placental transfer | Crosses placenta; evidence of transfer in human studies. |
| Breastfeeding | Excreted in milk; use caution, may cause adverse effects in infant such as jaundice and breast enlargement. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy category X. Combination hormonal contraceptives are contraindicated in pregnancy due to known risks to the fetus, including cardiovascular and limb defects from first-trimester exposure, and potential feminization of male fetuses from progestin exposure. Post-conception use is not indicated; if exposure occurs, evaluate for pregnancy. |
| Fetal Monitoring | Monitor for pregnancy before initiation and during use if pregnancy suspected. If inadvertent use during pregnancy, perform fetal ultrasound to assess for anomalies. No specific fetal monitoring required beyond standard prenatal care if exposure occurs. |
| Fertility Effects | Suppresses ovulation, thickens cervical mucus, and alters endometrial lining, resulting in contraceptive effect. Upon discontinuation, fertility returns, but there may be a short-term delay in resumption of ovulation, especially with prolonged use. No permanent negative effects on fertility. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from COC use. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use COCs.
| Common Effects | Nausea, Headache, Breast tenderness, Irregular bleeding or spotting, Weight changes, Mood changes |
| Serious Effects | Venous thromboembolism (VTE), Arterial thromboembolism (e.g., stroke, myocardial infarction), Hypertension, Hepatic adenoma or hepatocellular carcinoma, Gallbladder disease, Hyperkalemia (due to drospirenone's antimineralocorticoid activity) |
PregnancyHistory of thromboembolic disordersLiver diseaseUndiagnosed abnormal uterine bleedingKnown or suspected breast carcinoma
| Precautions | Thrombotic disorders (DVT, PE, stroke, MI), Carcinoma (breast, cervical, liver), Hepatic disease (jaundice, cholestasis), Hypertension, Carbohydrate/lipid effects, Headache/migraine, Bleeding irregularities, Drug interactions (CYP3A4 inducers/inhibitors), Depression, Gallbladder disease, Hereditary angioedema |
| Food/Dietary | Grapefruit juice may increase estrogen levels and risk of adverse effects; avoid large quantities. Iron absorption is enhanced by vitamin C (e.g., orange juice) and inhibited by tannins (tea, coffee), calcium (dairy), and phytates (whole grains); separate iron intake from these foods by at least 2 hours. Take with food to reduce GI upset. |
| Clinical Pearls | LO-BLISOVI FE (norethindrone acetate/ethinyl estradiol/ferrous fumarate) is a combined oral contraceptive with iron supplementation. The iron component (75 mg ferrous fumarate) compensates for menstrual blood loss. Administer at the same time daily to maintain stable hormone levels. Missed doses increase risk of breakthrough bleeding and contraceptive failure. Consider non-oral contraceptives in patients with malabsorption or vomiting. |
| Patient Advice | Take one tablet daily at the same time with food to reduce nausea. · Missed doses: if one dose is missed >12 hours, take it immediately and continue; if two doses are missed, take two tablets and use backup contraception for 7 days. · Iron tablets may cause dark stools; this is harmless. · Report severe headache, chest pain, leg swelling, or vision changes immediately. · Do not smoke while taking this medication; smoking increases risk of blood clots. · Store in original blister pack; do not remove desiccant. |
Loading safety data…